ALXO
ALX ONCOLOGY HOLDINGS INC
NASDAQ · Healthcare · Biotechnology · US
$1.14
+7.55%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.06
From 52W high−56.15%
Volume1.01M
Market cap$157.64M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.06
From 52W high
−56.15%
Volume
1.01M
Market cap
$157.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
35.8
MomentumView details →
1D Return
+7.55%
YTD Return
−4.87%
SummaryUpdated Jun 1, 2026
ALX Oncology Holdings Inc. (NASDAQ:ALXO) is a clinical-stage immuno-oncology biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cancer therapies that harness the body's immune system to fight tumors. ALX Oncology is currently advancing multiple drug candidates through clinical trials, with its lead program targeting a cellular pathway that cancer cells use to evade immune detection.
Similar companies
Latest newsMore news →
ALX ONCOLOGY HOLDINGS INC entered into an exchange agreement under which stockholders surrendered 13,353,384 common shares for no consideration and the company issued pre-funded warrants to purchase 13,353,384 common shares at $0.001 per share.4d agoALX Oncology announced the publication in Nature Medicine of ASPEN-06 Phase 2 clinical data showing evorpacept plus trastuzumab, ramucirumab and paclitaxel achieved a 40.3% overall response rate versus 26.6% for control in HER2-positive gastric cancer.22d ago